Searchable abstracts of presentations at key conferences in endocrinology

ea0038p449 | Thyroid | SFEBES2015

Serum thyroid stimulating hormone concentration after withdrawal of thionamides as a predictor of Graves’ disease outcome

Nalla Preethi , Adlan Mohamed , Premawardhana Lakdasa D

Introduction: Despite high rates of recurrence after anti-thyroid drug (ATD) withdrawal, ATD (mainly Carbmazole) remain the first line of treatment for Graves’ disease (GD) in the UK. Limited retrospective observational studies have shown that a low TSH post ATD withdrawal had a positive predictive value of 70% and a negative predictive value of 62% (specificity 85%) for relapse of Graves’ disease.Aim: We wished to determine the relationship be...

ea0055p12 | Poster Presentations | SFEEU2018

Idiopathic FSH deficiency

Ravindran Ravikumar , Witczak Justyna , Premawardhana Lakdasa , Adlan Mohamed

Case history: A 24-year-old previously healthy male presented to his GP with unilateral “gynaecomastia”, prompting investigations which showed a low FSH of 0.7 (1–12 IU/l). He had normal libido, erectile function, and a normal sense of smell. He had no children. He was subsequently investigated for persistent dysuria but imaging and cystoscopy were entirely normal. He was a non-smoker who took little alcohol and worked as an insurance agent. His past medical his...

ea0038p72 | Clinical practice/governance and case reports | SFEBES2015

A woman with thyroid metastases 21 years after renal carcinoma excision, with biphasic thyroid dysfunction on sunitinib

Nalla Preethi , Talabani Bnar , Adlan Mohamed , Premawardhana Lakdasa

Introduction: The commonest metastases to the thyroid are from renal cell carcinomas (RCC) and 23–48% of all thyroid metastases are RCCs. They may occur many years after RCC excision, the longest reported latent period being 20 years. Sunitinib (SUN), a multiple targeted anti-cancer drug, is increasingly used for RCC therapy but may cause thyroid dysfunction in some – usually hypothyroidism. We report a patient who presented with thyroid metastases 21 years after RCC...

ea0070ep30 | Adrenal and Cardiovascular Endocrinology | ECE2020

The utility of pre-test cortisol and other parameters in the prediction of short Synacthen test failure

Ravindran Ravikumar , Kumar Asit , Capatana Florin , Carter Jo , Adlan Mohamed , Premawardhana Lakdasa

Introduction: Short Synacthen tests (SST) are expensive, inconvenient, time consuming and subject to Synacthen availability. Any strategy reducing the need for SSTs will improve its cost effectiveness and also improve patient satisfaction. In this regard indications for SST and assay specific pre-test cortisol levels (not all SSTs are done at 0900 h) may have clinical utility.Methods: We retrospectively examined the indications for, time and place of tes...

ea0028p93 | Clinical practice/governance and case reports | SFEBES2012

Intractable nephrogenic diabetes insipidus, transient thyroiditis and hypercalcaemia complicating long term Lithium therapy

Kamath Chandan , Govindan Jyotish , Premawardhana Amila , Wood Sarah , Adlan Mohamed , Premawardhana Lakdasa

Introduction Lithium (Li) is an effective treatment for bipolar and schizo-affective disorders. It has a narrow therapeutic index, and produces common side effects when this is exceeded. Li causes endocrine disruption by predictable and some hitherto unclear mechanisms. We present a subject who developed multiple Li induced endocrinopathies concurrently, and was a therapeutic challenge. Case presentation and investigations Mr. DM had been on Li for 10 years and developed polyu...

ea0050p390 | Thyroid | SFEBES2017

Thyrotrophin receptor antibodies (TRAb) and other autoantibodies after treatment of Graves’ disease

Nalla Preethi , Young Stuart , Sanders Jane , Adlan Mohamed , Furmaniak Judwiga , Chen Shue , Rees Smith Bernard , Premawardhana Lakadasa

Introduction: Following treatment of Graves’ disease (GD), levels of thyrotropin receptor autoantibodies (TRAb) tend to decrease depending on treatment modality and length of follow up. We have assessed TRAb biological activity at follow up, years after GD treatment.Subjects and methods: TRAb concentration and biological activity were measured in 69 GD patients (59 females; 10 males; median age 59 years; TRAb positive at diagnosis), with follow up r...

ea0050p390 | Thyroid | SFEBES2017

Thyrotrophin receptor antibodies (TRAb) and other autoantibodies after treatment of Graves’ disease

Nalla Preethi , Young Stuart , Sanders Jane , Adlan Mohamed , Furmaniak Judwiga , Chen Shue , Rees Smith Bernard , Premawardhana Lakadasa

Introduction: Following treatment of Graves’ disease (GD), levels of thyrotropin receptor autoantibodies (TRAb) tend to decrease depending on treatment modality and length of follow up. We have assessed TRAb biological activity at follow up, years after GD treatment.Subjects and methods: TRAb concentration and biological activity were measured in 69 GD patients (59 females; 10 males; median age 59 years; TRAb positive at diagnosis), with follow up r...